ARROWHEAD PHARMACEUTICALS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $224.15 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $99.63M, a 58.57% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-06-30 was $240.48M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month |
|---|---|---|---|
| 2026-06-30 | $99.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $224.15M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $124.52M 10-Q · filed 2026-05-07 | ||
| 2025-06-30 | $240.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $587.88M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $347.40M 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |